CGM Linked to More Time in Range - Scorecard - MDSpire

CGM Linked to More Time in Range

  • By

  • Andrea Surnit

  • July 14, 2026

  • 4 min

Share

Clinical Scorecard: CGM Linked to More Time in Range

At a Glance

CategoryDetail
ConditionType 2 Diabetes with End-Stage Kidney Failure
Key MechanismsReal-time continuous glucose monitoring improves secondary measures of glycemic control.
Target PopulationPatients aged 18 to 80 years with insulin-treated type 2 diabetes receiving maintenance hemodialysis.
Care SettingDialysis centers

Key Highlights

  • Real-time continuous glucose monitoring improved time in range from 55% to 63%.
  • Mean glucose levels decreased from 188 mg/dL to 174 mg/dL with continuous monitoring.
  • Time above 180 mg/dL decreased from 44% to 35% with continuous monitoring.
  • No significant difference in time below 70 mg/dL between monitoring strategies.
  • Hyperglycemic episodes remained common in both monitoring periods.

Guideline-Based Recommendations

Diagnosis

    Management

    • Use real-time continuous glucose monitoring for improved glycemic control in insulin-treated patients.

    Monitoring & Follow-up

    • Monitor glucose levels regularly, with emphasis on time in range and hyperglycemia.

    Risks

    • Increased level 1 hypoglycemic episodes during continuous glucose monitoring.

    Patient & Prescribing Data

    Insulin-treated patients with type 2 diabetes on maintenance hemodialysis.

    Continuous glucose monitoring may enhance glycemic management.

    Clinical Best Practices

    • Educate patients on sensor trend arrows and glucose patterns.
    • Encourage regular capillary testing alongside continuous monitoring.

    Related Resources & Content

    Original Source(s)

    Related Content